PBM and Supply Chain Transparency – A-2840
The Assembly Health Committee also considered legislation put forth by the Governor and introduced by the Legislature to address prescription drug affordability. BioNJ commends Assembly Health Committee Chairman Herb Conaway and Assembly Health Committee members for their insightful comments, questions and discussion. BioNJ shares the recognition that there should be transparency across the entire supply chain, as proposed in A-2840. However, BioNJ respectfully requests amendments that would enhance and enable data collection and compliance, eliminate anti-competitive disclosure and reduce the risk of delayed access for Patients, while still allowing for meaningful transparency. The advance notification language in this bill would potentially delay launch of a drug for 60 days, essentially delaying Patient access to a new innovative medicine.
BioNJ stands ready to continue to work with the Administration and Legislature on amendments to ensure that these policies will have a positive impact on Patient affordability and access to medicines.
BioNJ strongly supports legislative measures that will enhance the ability of Patients to access our industry’s lifesaving treatments – including A-2839, which places a cap on the out-of-pocket contribution for any covered person prescribed insulin, an epinephrine auto-injector device, or a prescription asthma inhaler.
BioNJ applauds the independent pharmacists and the NJ Pharmacists Association for their effective testimony that shed light on PBM practices and the need for meaningful transparency.
Click here to read BioNJ President & CEO Debbie Hart’s testimony. Click here to watch a replay of the Assembly Health Committee hearing. Click here for copy of A-2840.
